Brendan Smith

Q: How accurate are Brendan Smith's stock ratings?

About 69% of Brendan's ratings were profitable over a one-year hold, with an average return of +20.7% per rating, measured by 13Foresight from historical prices.

Q: How is Brendan ranked?

Brendan Smith is ranked #82 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

TD Cowen

Wall Street Analyst

★★★★★

#82

on 13Foresight · ranked by our own returns

71%

Success Rate

+21.2%

Average Return

36 of 51 calls profitable · +17.0% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 71% of Brendan Smith's ratings turned a profit when each position was held for 1 year — averaging +21.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

96 Buy 39 Hold 0 Sell

Brendan's Stock Coverage 26 ratings · 2026-08-11

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
PASG Passage Bio	Aug 10, 2026	HOLD	Buy +300.5% avg upside 14 analysts	—	·	·
DNA Ginkgo Bioworks Holdings	Aug 07, 2026	HOLD	Strong Sell -8.1% avg upside 6 analysts	$9.00 17.67% Upside	-4.0%	·
BLFS BioLife Solutions	Aug 07, 2026	HOLD	Buy -14.8% avg upside 17 analysts	$31.00 10.52% Downside	+0.0%	·
HALO Halozyme	Aug 07, 2026	BUY	Strong Buy -36.5% avg upside 20 analysts	$105.00 2.31% Upside	+0.9%	·
OABI OmniAb	Aug 06, 2026	BUY	Strong Buy +133.4% avg upside 10 analysts	$3.00 11.59% Downside	+37.5%	·
SDGR Schrodinger	Aug 05, 2026	BUY	Strong Buy +51.8% avg upside 14 analysts	$20.00 6.60% Upside	+16.9%	·
AZTA Azenta	Aug 05, 2026	HOLD	Buy +47.5% avg upside 13 analysts	$33.00 1.07% Downside	+4.8%	·
CTKB Cytek Biosciences	Aug 05, 2026	HOLD	Buy +22.1% avg upside 5 analysts	$5.00 7.32% Upside	-0.5%	·
TKNO Alpha Teknova	Aug 05, 2026	BUY	Strong Buy +93.9% avg upside 7 analysts	$7.00 4.12% Upside	+15.3%	·
RXRX Recursion Pharmaceuticals	Aug 05, 2026	HOLD	Buy +143.2% avg upside 12 analysts	—	+6.2%	·
ABCL AbCellera Biologics	Aug 05, 2026	BUY	Strong Buy +57.4% avg upside 15 analysts	—	+17.1%	·
CERT Certara	Aug 04, 2026	BUY	Buy +62.9% avg upside 22 analysts	$9.00 11.54% Upside	+4.2%	·
TWST Twist Bioscience	Aug 03, 2026	BUY	Strong Buy -27.5% avg upside 14 analysts	$115.00 7.94% Downside	+22.6%	·
RGEN Repligen	Jul 28, 2026	BUY	Strong Buy +6.0% avg upside 25 analysts	$200.00 22.62% Upside	+6.3%	·
WST West Pharmaceutical Services	Jul 23, 2026	BUY	Strong Buy +3.7% avg upside 18 analysts	$410.00 16.42% Upside	-0.3%	·
EVO Evotec AG	Jul 15, 2026	HOLD	Buy +307.6% avg upside 9 analysts	$2.00 3.89% Downside	+3.5%	·
EVT Eaton Vance Tax-Advantaged Dividend Income Fund	Jul 14, 2026	HOLD	Hold -93.0% avg upside 1 analyst	$2.00 93.05% Downside	+6.6%	·
SLP Simulations Plus	Jul 09, 2026	HOLD	Buy +106.6% avg upside 11 analysts	$16.00 12.83% Downside	+0.1%	·
RPID Rapid Micro Biosystems	May 27, 2026	BUY	Strong Buy +406.6% avg upside 6 analysts	—	+6.1%	·
MXCT MaxCyte	May 12, 2026	BUY	Buy +233.2% avg upside 5 analysts	—	+51.2%	·
ABSI AbSci	May 07, 2026	BUY	Strong Buy +34.0% avg upside 18 analysts	—	+56.7%	·
CDXS Codexis	May 07, 2026	HOLD	Strong Buy +579.1% avg upside 13 analysts	$2.00 33.33% Upside	-41.5%	·
MASS 908 Devices	May 06, 2026	BUY	Strong Buy +24.8% avg upside 4 analysts	—	+10.2%	·
ARWR Arrowhead Pharmaceuticals	May 13, 2025	BUY	Strong Buy -14.8% avg upside 27 analysts	—	+409.7%	·
DNLI Denali Therapeutics	May 06, 2025	BUY	Strong Buy +54.6% avg upside 24 analysts	—	+46.1%	·
NVAX Novavax	Nov 12, 2024	HOLD	Hold +192.5% avg upside 20 analysts	$9.00 14.03% Upside	-14.9%	·

🔒 21 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Brendan Smith — Frequently Asked Questions

How accurate are Brendan Smith's stock ratings?

Based on the calls 13Foresight could measure, about 69% of Brendan's ratings were profitable over a one-year hold, with an average return of +20.7% per rating, or +16.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Brendan ranked on 13Foresight?

Brendan Smith is currently ranked #82 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Brendan cover?

Brendan most recently has ratings on PASG, DNA, BLFS, HALO, OABI, SDGR, AZTA, CTKB, TKNO, RXRX, ABCL, CERT and 14 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Brendan Smith

Rating Distribution

Welcome to 13Foresight!